SHMT2 improves the m6A abundance of PPAT mRNA by offering methyl donor SAM, allowing IGF2BP2 to enhance the stability and expression of PPAT, regulating cell cycle to promote proliferation in renal cell carcinoma [55]. This evidence concerns the gene IGF2BP2 and hereditary clear cell renal cell carcinoma.